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Abstract
Background: A growing body of evidence suggests that the plasma concentration of the neurofilament light chain
(NfL) might be considered a plasma biomarker for the screening of neurodegeneration in Alzheimer’s disease (AD).
Methods: With a single molecule array method (Simoa, Quanterix), plasma NfL concentrations were measured in
99 subjects with AD at the stage of mild cognitive impairment (MCI-AD; n = 25) or at the stage of early dementia
(ADD; n = 33), and in nondemented controls (n = 41); in all patients, the clinical diagnoses were in accordance with
the results of the four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1–42, Aβ42/40, Tau, and pTau181),
interpreted according to the Erlangen Score algorithm. The influence of preanalytical storage procedures on the
NfL in plasma was tested on samples exposed to six different conditions.
Results: NfL concentrations significantly increased in the samples exposed to more than one freezing/thawing cycle,
and in those stored for 5 days at room temperature or at 4 °C. Compared with the control group of nondemented
subjects (22.0 ± 12.4 pg/mL), the unadjusted plasma NfL concentration was highly significantly higher in the MCI-AD
group (38.1 ± 15.9 pg/mL, p < 0.005) and even further elevated in the ADD group (49.1 ± 28.4 pg/mL; p < 0.001). A
significant association between NfL and age (ρ = 0.65, p < 0.001) was observed; after correcting for age, the difference
in NfL concentrations between AD and controls remained significant (p = 0.044). At the cutoff value of 25.7 pg/mL,
unconditional sensitivity, specificity, and accuracy were 0.84, 0.78, and 0.82, respectively. Unadjusted correlation
between plasma NfL and Mini Mental State Examination (MMSE) across all patients was moderate but significant
(r = −0.49, p < 0.001). We observed an overall significant correlation between plasma NfL and the CSF biomarkers, but
this correlation was not observed within the diagnostic groups.
Conclusions: This study confirms increased concentrations of plasma NfL in patients with Alzheimer’s disease
compared with nondemented controls.
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Background
Cerebrospinal fluid (CSF) biomarkers have been extensively
studied as tools for an early diagnosis of Alzheimer’s disease
(AD) [1] and have proven to be cheaper, less demanding in
terms of infrastructure and patient management, and most
probably capable of showing pathologic alterations slightly
earlier than other diagnostic modalities such as, for example,
positron emission tomography; the relative invasiveness of
the two modalities remains disputable [2]. In particular, the
four core CSF biomarkers, amyloid β (Aβ)1–42, Aβ42/40 ra-
tio, Tau, and pTau181, reliably support AD diagnostics
reflecting the hallmark AD pathologies, i.e., amyloidosis and
neurodegeneration [3]. Lumbar puncture (LP) is a routine
clinical procedure with a low incidence of complications [4].
Nevertheless, collection of CSF is accompanied by proced-
ural efforts and inconvenience for subjects, ultimately
preventing its use as a screening tool in early, asymptomatic
cases and it can also be challenging to use for repetitive
monitoring of the disease progression. Hence, there is a
strong need to develop blood-based biomarkers that, when
applied in a proper context of use, could serve as targeted
and relative noninvasive screening tests [5].
Neurofilaments (Nf) consist of three types of pro-
tein chains, differing in molecular mass: a light chain (NfL)
of 68 kD, an intermediate chain of 150 kD, and a heavy chain
of 190 to 210 kD, and are major components of axonal cyto-
skeleton [6]. Each subunit is composed of a double-stranded,
highly conserved α-helical core domain, bordered by a head
N-terminus and a tail C-terminus. Nf are highly phosphory-
lated proteins, and the degree of this phosphorylation deter-
mines the axon diameter [6]. Axonal damage leads to release
of Nf molecules into the extracellular space and, conse-
quently, into body fluids, such as the CSF or plasma. In line
with this, increased blood NfL concentrations were reported
in neurodegenerative and neuroinflammatory disorders
[7–9]. A very recent report by Mattsson et al. convincingly
concludes that plasma NfL could be considered a neuro-
degeneration biomarker in AD [10].
In this study, we measured NfL concentrations in
plasma samples of AD patients at the stages of mild cogni-
tive impairment (MCI) and early dementia (ADD), and
nondemented controls. In all our subjects the clinical and
neuropsychologic diagnoses were in accordance with the
results of their four core CSF biomarkers (Aβ1–42, Aβ42/
40, Tau, and pTau181). For the validation of the assay, we
further tested the influence of different preanalytical sam-
ple handling procedures (repetitive freezing/thawing, and
storage at room temperature or in a refrigerator) on the
concentrations of plasma NfL.
Methods
Patients and blood collection; diagnostic CSF tests
The ethical committee of the University of Erlangen-
Nuremberg approved the study, and all patients or their
caregivers gave their written consent. Blood samples
were obtained from 99 patients at the Department of
Psychiatry and Psychotherapy, Universitätsklinikum
Erlangen, and categorized into three groups: nondemen-
ted controls (Controls, n = 41), MCI with high probabil-
ity of AD pathology (MCI-AD, n = 25), and AD in early
dementia stage (ADD, n = 33). According to the revised
NINCDS-ADRDA criteria [11, 12], diagnoses were made
after clinical evaluation, neuropsychological testing with
the CERAD+ battery, magnetic resonance imaging
(MRI), duplex sonography of the carotids and brain
arteries as well as electroencephalographic (EEG) re-
cordings. The distinction between dementia and MCI
was made on the basis of the clinical assessment; pa-
tients with MCI had an objectively measureable cogni-
tive decline but their independence regarding functional
life abilities was preserved, which means that the revised
NINCDS-ADRDA diagnostic criteria of dementia were
not fulfilled. In all cases, the clinical and neuropsycholo-
gic diagnoses remained in accord with the results of the
four core biomarkers of neurochemical dementia
diagnostics (NDD), all analyzed by enzyme-linked im-
munosorbent assays (ELISA): Aβ1–42 (IBL International,
Hamburg, Germany), Aβ42/40 (IBL International), Tau
(Fujirebio Europe, Ghent, Belgium), and pTau181 (Fujirebio
Europe), interpreted according to the Erlangen Score
algorithm (ES), [13, 14]. All control cases had normal CSF
results (ES ≤ 1) and all MCI-AD and ADD patients had
profoundly pathological CSF results (ES = 4). Vascular
copathology was not an exclusion criterion in our study.
Blood was collected by venipuncture into standard
polypropylene EDTA test tubes (Sarstedt, Nümbrecht,
Germany) followed by centrifugation; the obtained plasma
was portioned into approximate 500 μL aliquots, fro-
zen at −80 °C, and kept unthawed until the analyses.
Samples for testing the preanalytical storage conditions
For testing of the influence of the preanalytical storage
conditions, blood samples were collected from five do-
nors, and the plasma was generated as above. Immediately
thereafter, from each sample six aliquots were prepared,
resulting in a matrix of 5 cases × 6 aliquots (conditions): a)
one aliquot was immediately frozen at −80 °C, and served
as a reference sample; b) one aliquot was frozen at −80 °C
and exposed to one thawing/refreezing (1 × F/T) cycle; c)
one aliquot was frozen at −80 °C and exposed to two F/T -
cycles; d) one aliquot was frozen at −80 °C and ex-
posed to three F/T cycles; e) one aliquot was stored
for 5 days at 4 °C; and f) one aliquot was stored for 5 days
in the dark at room temperature (~ 21 °C). Following the
isochronous testing strategy [15], after 5 days at either
room temperature or 4 °C, the aliquots (e) and (f) were
transferred to the reference condition (−80 °C freezer) and
kept frozen until analyses.
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Simoa assay
For analysis of NfL concentrations, the samples were
transported on dry ice to the Clinical Neurochemistry
Laboratory, Sahlgrenska University Hospital. The ana-
lyses were performed using an in-house assay on the sin-
gle molecule array platform (Simoa; Quanterix,
Lexington, MA, USA), as previously described in detail
[16]. This method has an analytical sensitivity of
0.62 pg/mL [7]. All measurements were performed by
board-certified laboratory technicians who were blinded
to clinical data.
Statistical analysis
The number of samples was estimated considering the be-
tween-group differences reported in the available litera-
ture, and with the significance and the power set to 0.05
and 0.9, respectively. If not stated otherwise, the results
are presented as averages ± standard deviations (SD) or
95% confidence intervals (95% CI). Correlations between
continuous variables, unadjusted for other covariates, are
presented as Pearson (r) or Spearman (ρ) correlation coef-
ficients, as indicated. Partial correlation was used to
estimate the correlation coefficients and their significances
between Mini Mental State Examination (MMSE) scores
and the concentrations of plasma NfL and the CSF bio-
markers, conditional on diagnostic categories. Differences
across multiple categories were tested with analysis of
variance (ANOVA) followed by post-hoc tests with appro-
priate corrections for multiple comparisons.
Association of the preanalytical storage conditions
and the NfL concentrations was tested with a vari-
ance component model with conditions crossed with
samples. A linear regression was used to model NfL
plasma concentrations in the diagnostic groups, ad-
justed for patient age, including interaction term
age-by-disease status. The models were compared
with likelihood ratio (LR) test on indicated degrees of
freedom (df ).
The NfL concentration cutoff separating controls from
AD patients was calculated at the maximized Youden
index. Logistic regression was used to model the sensi-
tivity and the specificity as a function of age according
to Coughlin et al. [17], slightly modified by introducing
interaction term for age-by-disease status. The test's ac-
curacy was defined as the probability of the agreement
between the result of the test and the disease status (re-
sponse = 1 if both positive or both negative, or 0 other-
wise), and was modeled, conditional on age, with logistic
regression. The area under the receiver operating char-
acteristic (ROC) curve (AUC) was calculated with a non-
parametric method. Fisher’s linear discriminant analysis
(LDA) was used to calculate parameters of the line opti-
mally separating the controls and the AD patients on
the basis of their NfL concentrations and age.
If not stated otherwise, estimates in logistic models
were obtained with the maximum likelihood (ML)
method. P < 0.05 was considered significant. All analyses
were performed with Stata 14.2 (StataCorp, College Sta-
tion, TX, USA).
Results
Plasma NfL assay performance
Two quality control (QC) samples spanning clinically
relevant concentrations of the analyte were analyzed in
duplicates two to three times in each run. For a QC
sample with a concentration of 12.5 pg/mL, repeatability
was 8.9% and intermediate precision was 11.0%. For a
QC sample with a concentration of 105.7 pg/mL, repeat-
ability and intermediate precision were both 6.4%.
Concentrations of NfL in plasma samples under different
storage conditions
Concentrations of NfL in aliquots of the five plasma sam-
ples with six different preanalytical treatment conditions
are presented in Fig. 1. Compared to the reference aliquot,
the concentrations of NfL under all conditions, except for
one cycle of thawing/refreezing, were slightly but signifi-
cantly higher (p < 0.05). After normalization, defining the
concentration in a reference aliquot as 1.00, the average
relative concentrations and their standard deviations in the
tested aliquots were: 1.07 ± 0.23 in the aliquots exposed to
one freezing/thawing cycle, 1.24 ± 0.23 in the aliquots
thawed and refrozen twice, 1.41 ± 0.42 in the aliquots
thawed and refrozen three times, 1.32 ± 0.26 in the aliquots
stored for 5 days at 4 °C, and 1.46 ± 0.21 in the aliquots
stored for 5 days at room temperature. The ML estimates
of the random parameters of the variance-components
model were ψ = 37.3 (variability of the random intercept,
i.e., between-sample), and θ = 1.94 (variability of the level-1
residual, i.e., within-sample), resulting in a within-sample
(intraclass) correlation ρ = 0.95.
Plasma NfL in nondemented controls, MCI-AD, and ADD
patients
Demographic characterization of the three groups consid-
ered in this study, the results of the CSF biomarkers, and
the plasma NfL concentrations are presented in Table 1.
Results of the NfL measurements in the three diagnostic
groups are presented in Fig. 2. Unadjusted for other
covariates and compared with the control group of nonde-
mented subjects (22.0 ± 12.4 pg/mL), average NfL concen-
trations were highly significantly higher in the MCI-AD
group (38.1 ± 15.9 pg/mL, p < 0.005), and even further ele-
vated in the ADD group (49.1 ± 28.4 pg/mL; p < 0.001).
The concentrations in the ADD group was also higher
compared with the MCI-AD group; however, this differ-
ence became borderline insignificant after Scheffe’s
post-hoc correction for multiple comparisons (p = 0.12).
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Taking into consideration that a) according to the
current concept of the AD continuum [18, 19], MCI-AD
is not a separate diagnostic entity but rather a stage of
AD, and b) MCI-AD and ADD cases had, expectedly,
the same pattern of the pathologic CSF results, we
pooled the two groups into one diagnostic category (Alz-
heimer’s disease, AD) and contrasted it with the nonde-
mented controls. In Fig. 3, NfL concentrations in AD
and controls are plotted against age. Overall, we ob-
served a highly significant association between NfL and
age (ρ = 0.65, p < 0.001). After correcting for age, the dif-
ference in NfL concentrations between the two groups
remained statistically significant (p = 0.044). Since the
interaction term of age-by-disease status was insignifi-
cant (β = 0.365, p = 0.361), and did not improve the
model fit (LR test χ2(df = 1) = 0.87, p = 0.35), we excluded
it from further analyses. Using LDA, we finally estimated
the parameters of the line optimally separating the AD
patients from the controls: NfL (pg/mL) = −5.25 × age
(years) + 367.7, which resulted in 81% of cases being
properly categorized (sensitivity and specificity of 0.86
and 0.76, respectively).
Sensitivity, specificity, and accuracy of plasma NfL as a
potential AD biomarker
Figure 4 presents the performance of the plasma NfL
concentration in the setting of AD patients with positive
CSF biomarkers versus nondemented controls with
negative CSF biomarkers. Unadjusted for other variables,
the AUC of the ROC curve in the setting controls vs dis-
eased turned out reasonably large (0.853, 95% CI 0.772–
0.934; Fig. 4a). After introducing age to the model esti-
mating the ROC curve, the AUC increased insignifi-
cantly (p = 0.055) to 0.920 (95% CI 0.869–0.970). At the
cutoff maximizing Youden index, 25.7 pg/mL, uncondi-
tional sensitivity, specificity, and accuracy were 0.84,
0.78, and 0.82, respectively. Considering age differences
between the groups in this study, we consequently mod-
eled the performance characteristics of the test as a
function of age (Fig. 4b). While the sensitivity increased
with age, from 0.61 at 50 years to 0.91 at 80 years, the
specificity decreased from 0.89 to 0.20, respectively,
leaving the overall accuracy of the test practically un-
altered (0.84 and 0.80 at the age of 50 and 80 years,
respectively).
Fig. 1 Neurofilament light chain (NfL) plasma levels of samples with different preanalytical treatment. *p < 0.05, versus the reference (Ref.) sample
(frozen at −80 °C and unthawed). d days, F/T freeze/thaw cycle, n.s. not significant, RT room temperature
Table 1 Demographic characterization, CSF results, and NfL
concentrations in the diagnostic groups
Controls MCI-AD ADD
N (male + female) 41 (22 + 19) 25 (10 + 15) 33 (13 + 20)
Age (years) 52.5 ± 13.1 71.3 ± 8.4 70.8 ± 7.6
MMSE 29.3 ± 0.9a 26.7 ± 2.1b 21.2 ± 3.4
CSF Aβ1–42 (pg/mL) 1025 ± 308 585 ± 116 536 ± 114
CSF Aβ1–40 (pg/mL) 13,598 ± 4046 19,171 ± 5689 15,309 ± 4172
CSF Aβ42/40 0.076 ± 0.01 0.032 ± 0.01 0.036 ± 0.006
CSF Tau (pg/mL) 198 ± 64.4 631 ± 214 558 ± 178
CSF pTau181 (pg/mL) 37.3 ± 12.1 101.4 ± 29.8 89.9 ± 18.4
Plasma NfL (pg/mL) 22.0 ± 12.4 38.1 ± 15.9 49.1 ± 28.4
Values are shown as averages ± standard deviations or as numbers per group
Aβ amyloid β, AD Alzheimer’s disease, ADD Alzheimer’s disease dementia, CSF
cerebrospinal fluid, MCI mild cognitive impairment, MMSE Mini Mental State
Examination, NfL neurofilament light chain
aAvailable in 22 cases
bAvailable in 23 cases
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The unadjusted correlation between plasma NfL and
MMSE score was moderate and highly significant (r =
−0.49, p < 0.001; Fig. 5). After controlling for the diag-
nostic categories, the coefficient became weaker, albeit
still significant (r = −0.24, p = 0.036). None of the CSF
biomarkers correlated significantly with the MMSE score
after controlling for the diagnostic categories (p > 0.2;
data not shown).
Correlation of plasma NfL with the four core CSF
biomarkers
Without taking diagnostic categories into consideration,
NfL in plasma correlated highly significantly (p < 0.001)
with all CSF biomarkers except Aβ1–40 (as expected,
positively with Tau and pTau181, and negatively with
Aβ1–42 and Aβ42/40; data not shown). This correlation
became insignificant for all CSF biomarkers (p > 0.35)
Fig. 2 Unadjusted neurofilament light chain (NfL) concentrations in the three diagnostic categories. A borderline insignificant (p = 0.11 after
Scheffe correction) tendency was observed towards higher concentrations in Alzheimer’s disease dementia (ADD) compared with mild cognitive
impairment Alzheimer’s disease (MCI-AD). The green horizontal line represents the cutoff at the maximized Youden index (25.7 pg/mL), leading to
the unadjusted diagnostic accuracy of 82% in the setting of controls versus AD (MCI-AD and ADD). *p < 0.05
Fig. 3 Neurofilament light chain (NfL) plasma levels plotted against age in nondemented controls (green) and the AD patients (a combined
group of MCI-AD and ADD subjects, red). The black dotted line represents the optimal separation of the two groups according to Fisher’s LDA
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when the diagnoses were taken into account. Figure 6
presents, exemplarily, a significant correlation between
plasma NfL and CSF Tau across all patients taken
together (Fig. 6a) and a lack of within-groups
correlation between the two analytes (overall p = 0.64)
when the three diagnostic groups are treated separ-
ately (Fig. 6b−d).
Discussion
A growing body of literature postulates a potential appli-
cation of the plasma concentration of the light chain of
the neurofilament protein as a screening tool for neuro-
degeneration. In our study, the plasma NfL concentra-
tion was found to be significantly higher in the AD
patients, whose diagnoses were in accordance with the
pathological results of the CSF biomarkers, compared
with the nondemented control subjects, whose normal
cognitive status was in accordance with the unaltered re-
sults of their CSF biomarkers. Within the AD group, we
observed a tendency towards higher NfL concentrations
in patients at the stage of early dementia compared with
the stage of MCI. Plasma NfL concentrations correlated
inversely with the global cognitive status measured by
the MMSE results. Finally, we also provide evidence for
the influence of the preanalytical sample handling on the
plasma NfL concentrations.
We started our study by examining the influence of sam-
ple handling procedures on plasma NfL concentrations.
Fig. 4 a Unadjusted ROC curve in the setting of controls vs. AD. b Sensitivity (blue), specificity (brown), and accuracy (green) as functions of age.
AUC area under the curve, CI confidence interval, SE standard error
Fig. 5 Correlation between plasma neurofilament light chain (NfL) concentrations and the Mini Mental State Examination (MMSE) results
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We believe this is a critically important aspect; for example,
a sample’s storage and transportation to distant laboratories
is a nontrivial issue and has practical implications. Com-
pared with a reference sample (i.e., a deep-frozen aliquot
stored unthawed until analysis), we observed a slight but
significant increase in the concentrations in the aliquots
thawed and refrozen twice or three times, kept for 5 days at
the room temperature, or stored in a refrigerator. In con-
trast, one thawing/refreezing cycle did not systematically
alter the NfL concentration, but resulted in nonsystematic
changes, i.e., the concentrations increased in some samples
but decreased in others, resulting in increased variability
but an unchanged average. Whereas in most cases a de-
crease in the concentration of a protein with storage time
or under thawing/refreezing is expected, it is known that
some proteins, for example serum albumin, tend to in-
crease in concentration after repetitive thawing/refreezing
[20]. Similarly, in our previous studies, an unsystematic
increase in CSF Aβ1–42, Aβ1–40, and Tau in some, but
not all, aliquots exposed for more than two thawing/re-
freezing cycles was observed [21, 22]. As an explanation, a
release of NfL monomers from aggregates, known to form
in certain neurodegeneration disorders [23], might be
considered. Interestingly, the data on the stability of NfL in
the CSF are ambiguous; whereas one study found rapid de-
cline of concentrations at room temperature or 4 °C [24],
no changes were observed in another study until 3 days,
followed by a subsequent decrease [25]. In any case, it
seems reasonable to postulate sending the material to dis-
tant laboratories deeply frozen and avoiding more than one
intermediate thawing/refreezing cycle.
In agreement with recently published studies on spor-
adic AD [10, 26, 27] and familial AD (FAD) [28], we
found increased plasma NfL concentrations in AD pa-
tients in the dementia stage (ADD) as well as in MCI
subjects with a high probability of underlying AD path-
ology (MCI-AD), compared with nondemented controls.
The results of the current study confirm those reported
by Mattsson et al. obtained with the same method and
in the same laboratory but on different patient cohorts
[10], not only in terms of the average concentrations
and their biological variability (coefficients of variation),
but also in terms of the NfL performance as a potential
plasma diagnostic test. In both studies, almost identical
areas under the ROC curves, contrasting AD patients
versus nondemented controls, were obtained (0.853 and
0.87, respectively). A slightly higher average NfL concen-
tration in the controls reported by Mattsson et al. com-
pared with the present study can be explained by the
fact that one-third of the controls in the previous
paper showed Aβ positivity, whereas in the current study
positive Aβ CSF results excluded a subject as a control.
This is due to the fact that, in contrast to the papers
published previously, patients in the current study were
included only if their clinical and neuropsychological
diagnoses stayed in agreement with the outcome of the
Fig. 6 Plasma neurofilament light chain (NfL) plotted against cerebrospinal fluid (CSF) Tau. a. Overall moderate, highly significant correlation
between plasma NfL and CSF Tau; lacking within-group correlation between plasma NfL and CSF Tau in the controls (b), MCI-AD (c), and ADD (d)
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four core CSF biomarkers (Aβ1–42, Aβ42/40, Tau, and
pTau181) conservatively interpreted according to the Er-
langen Score algorithm [13, 14]. We are aware that such
an approach has advantages and disadvantages; it en-
ables more reliable stratification of the cases, but it ex-
cludes the possibility of a direct comparison of the
diagnostic utility of the plasma NfL with any of the CSF
biomarkers.
Our finding of a positive association between plasma
NfL concentration and age is in agreement with
previously reported studies on plasma [9, 10] and CSF
[29, 30]. A weak but significant association between
serum NfL and age at onset of a disease was also reported
in primary progressive aphasia (PPA) [8]; however, another
study did not find a correlation of NfL with age after
adjusting for the estimated age of onset of a disease in
FAD [28]. Mechanisms of this age-dependent increase in
the NfL concentrations in body fluids, and also in persons
without clinical signs of neurodegeneration, are unclear
thus far. It was hypothesized that aging leads to a subclin-
ical axonal degeneration and, in consequence, to the re-
lease of Nf molecules [29]. The same group also proposed
that subclinical cerebrovascular changes might be consid-
ered as an explanation, since cerebrovascular pathology is
common and known to increase with age; finally, vascular
copathology is also commonly observed in AD [31]. Irre-
spective of the underlying mechanisms, the association of
the NfL concentrations with age has implications for the
diagnosis-oriented interpretation of the results. First, an
age-dependent cutoff needs to be established, and calcula-
tion of such a cutoff is not a trivial task. Perhaps the best
approach is by applying such statistical tools such as LDA;
in such a case, however, the slope of the line discriminat-
ing the groups (i.e., the age-dependent cutoff) clearly
depends on the distribution of the parameters in question
(here NfL concentrations and age) in these groups. If they
are not age-matched, as in our study and in some other
reports [27, 28], a line best discriminating AD patients
from the controls has a negative slope, which might look
contradictory to common sense (i.e., in spite of NfL con-
centration increasing with age, its cutoff decreases). This
would be different if the two groups were age-matched, as
in the study by Mattsson et al. [10]. In such a case, the dis-
criminatory line would have a positive slope (i.e., it would
increase with age). Secondly, metrics of the performance
of the NfL concentrations as a potential diagnostic test
also depend on age. In this study, we observed an increase
in the sensitivity at the cost of a decrease in the specificity
with increasing age, leaving overall accuracy practically
unaltered. Furthermore, we observed a slight, borderline
insignificant increase of the area under the ROC curve
with age. To the best of our knowledge, only Mattsson et
al. [10] evaluated the age-dependent AUC of the ROC
curve discriminating AD from healthy controls, observing
a slight decrease of the AUC from 0.87 to 0.79 when the
model was fitted with age, sex, and educational level, in-
stead of all variables considered in their study. We are not
aware of any report analyzing age-dependency of any
other metrics. We believe that the characteristics found in
this study, with an age-dependent increase in the sensitiv-
ity at the cost of the decreasing specificity clearly seen in
the age range of 60–80 years (i.e., in the range when
neurodegeneration is most commonly considered in the
diagnosis), further supports the postulated potential appli-
cation of the plasma NfL as a screening tool for neurode-
generation, rather than as a test for confirming AD
diagnosis.
In line with the recently published results [10], we
found an inverse correlation of plasma NfL concentra-
tions with MMSE results. In contrast, none of the CSF
biomarkers measured in this study correlated signifi-
cantly with the MMSE score after controlling for the
diagnostic categories. This finding supports our previous
results of a lack of association between MMSE score and
the CSF results [32, 33], and remains in agreement with
the generally accepted assumption that the CSF bio-
markers do not correlate with disease progression at the
stage of MCI and later [34]. Other studies provide evi-
dence that NfL plasma concentrations reflect the dynam-
ics of neurodegeneration processes measured with
different metrics. Steinacker et al. found an association be-
tween increased NfL concentration and functional decline
and progression of atrophy in the left frontal lobe of PPA
patients [8], and Weston et al. reported an association of
serum NfL concentration with the time from symptom
onset in FAD [28]. Similarly, increased CSF NfL was found
to correlate with decreased MMSE score and with faster
brain atrophy over time, as measured by changes in
whole-brain volume, ventricular volume, and hippocam-
pus volume in AD [35]. In multiple sclerosis, CSF NfL re-
flects acute axonal damage, and hence it might be
considered a prognostic biomarker (reviewed in [6]).
Similar to the previously published findings [10], we
observed a highly significant overall correlation of
plasma NfL with CSF biomarkers for AD pathology
when the diagnostic categories were not considered.
Confirming the previous report, the significance of this
correlation disappeared when the diagnostic groups were
evaluated separately. Such a correlation pattern, with
overall significant correlation that is not observed within
particular diagnostic groups, is not surprising when a
lack of association between the CSF biomarkers and the
disease dynamics as soon as the first cognitive symptoms
occur (i.e., from the MCI stage on) is taken into consid-
eration [34].
Perhaps the most important limitation of our study is
the relatively small, age-unmatched groups, which we
tried to counterbalance by controlling for age in all
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statistical analyses. It must be stressed, however, that
such discrepancy between age of AD patients and non-
demented controls simply reflects the reality that AD
patients are older.
Conclusion
In conclusion, we confirmed increased concentrations of
plasma NfL in Alzheimer’s disease; however, its future
potential application as a biomarker will have to take its
nonspecificity into account. We speculate that plasma
NfL will not be able to replace the CSF biomarkers of
neurodegeneration within a given diagnostic group, but
it could perhaps be considered as a potential screening
tool between the groups. Finally, we extended previous
studies with a systematic test for the influence of the
preanalytical sample handling procedures on the NfL
concentrations in plasma.
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